Sarepta Therapeutics Announces Participation in Upcoming Investor Conferences
Sarepta Therapeutics, Inc. announced that senior management will participate in two investor conferences in November 2026.
Stocks · News reference
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Sarepta Therapeutics has announced that it will release its financial results for the third quarter of 2026.
Sarepta Says SRP-1003 Cut Disease-Causing RNA In Cell Nucleus By Up To ~80% In Preclinical Myotonic Dystrophy Model
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.